Search Orphan Drug Designations and Approvals
-
Generic Name: | Hydroxyurea | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Trade Name: | Droxia | ||||||||||||||||
Date Designated: | 10/01/1990 | ||||||||||||||||
Orphan Designation: | Treatment of patients with sickle cell anemia as shown by the presence of hemoglobin S. | ||||||||||||||||
Orphan Designation Status: | Designated/Approved | ||||||||||||||||
Sponsor: |
Bristol-Myers Squibb Pharmaceutical Research Institute P.O. Box 4000 Princeton, New Jersey 08543 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
||||||||||||||||
Marketing approved: |
|||||||||||||||||
1 | Generic Name: | Hydroxyurea |
---|---|---|
Trade Name: | Droxia | |
Marketing Approval Date: | 02/25/1998 | |
Approved Labeled Indication: | To reduce the frequency of painful crises and to reduce the need for blood transfusions in adult patients with sickle cell anemia with recurrent moderate to severe painful crises (generally at least 3 during the preceding 12 months). | |
Exclusivity End Date: | 02/25/2005 | |
Exclusivity Protected Indication* : | ||
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-